Anixa Biosciences (ANIX) Income from Non-Controlling Interests (2018 - 2026)
Anixa Biosciences' (ANIX) quarterly Income from Non-Controlling Interests came in at -$20000.0 in Q2 2026, up 13.04% YoY from -$17692.3 in Q2 2025, and up 25.93% on a QoQ basis from -$27000.0 in Q4 2025.
Anixa Biosciences (ANIX) Income from Non-Controlling Interests (2018 - 2026) Analysis & Trends
Anixa Biosciences (ANIX) has 9 years of Income from Non-Controlling Interests data on file, last reported at -$20000.0 in Q2 2026.
- Quarterly Income from Non-Controlling Interests rose 13.04% year-over-year to -$20000.0 in Q2 2026, while the trailing twelve-month figure through Apr 2026 was -$92000.0 (up 23.33% YoY) and the FY2025 annual result came in at -$101000.0, up 29.86% from the prior year.
- Income from Non-Controlling Interests improved to -$20000.0 in Q2 2026, from -$27000.0 in the prior quarter.
- In the past five years, Income from Non-Controlling Interests ranged from a high of -$19000.0 in Q2 2023 to a low of -$53000.0 in Q4 2022.
- A 5-year average of -$32941.2 and a median of -$31000.0 in 2023 frame the typical range for Income from Non-Controlling Interests.
- Annual changes were most pronounced in 2023 — Income from Non-Controlling Interests surged 56.82% — and 2024, when it sank 115.79%.
- Tracing ANIX's Income from Non-Controlling Interests over 5 years: stood at -$53000.0 in 2022, then jumped by 41.51% to -$31000.0 in 2023, then advanced by 3.23% to -$30000.0 in 2024, then climbed by 10.0% to -$27000.0 in 2025, then increased by 25.93% to -$20000.0 in 2026.
- The last three Income from Non-Controlling Interests figures came in at -$20000.0 (Q2 2026), -$27000.0 (Q4 2025), and -$22000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 63.60 Mn |
| 10 | Anixa Biosciences | 123.62 Mn | 123.62 Mn | - | -20,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 30, 2026 | -20,000.00 |
| Oct 31, 2025 | -27,000.00 |
| Jul 31, 2025 | -22,000.00 |
| Apr 30, 2025 | -23,000.00 |
| Jan 31, 2025 | -29,000.00 |
| Oct 31, 2024 | -30,000.00 |
| Jul 31, 2024 | -38,000.00 |
| Apr 30, 2024 | -41,000.00 |
| Jan 31, 2024 | -35,000.00 |
| Oct 31, 2023 | -31,000.00 |
| Jul 31, 2023 | -37,000.00 |
| Apr 30, 2023 | -19,000.00 |
| Jan 31, 2023 | -32,000.00 |
| Oct 31, 2022 | -53,000.00 |
| Jul 31, 2022 | -29,000.00 |
| Apr 30, 2022 | -44,000.00 |
| Jan 31, 2022 | -50,000.00 |
| Oct 31, 2021 | -58,000.00 |
| Jul 31, 2021 | -54,000.00 |
| Apr 30, 2021 | -38,000.00 |